Center · Read · October 23, 2026
Oct 22 · Moderna and Merck's personalized mRNA melanoma vaccine cuts the risk of recurrence or death by 42%, and Moderna shares tumble after the data leaks early
Forbes: Moderna Stock Plunges 25% After Apparent Leak of Cancer Vaccine Data
Grade F (46/100). Market story: Moderna down about 26% by 2 p.m. after Phase 3 data surfaced early on Oncology Central, Citi's valuation downgrade, billionaire shareholders' losses
Lehrer score 46/100 (−24 own-voice claim/analysis: ¶6: 'Moderna has been on a remarkable—and likely unsustainable—trajectory' (own-voice verdict); −12 loaded wording: ¶4: 'the stock's sky-high pre-leak valuation' (loaded wording in the outlet's own voice); −18 omission: calls the results 'positive' but never gives the trial's finding, the 42% lower risk of recurrence or death that CNN and Just the News report). Fixed scale: 90+ A, 80s B, 70s C, 60s D, under 60 F → F.
¶6: 'Moderna has been on a remarkable—and likely unsustainable—trajectory' (own-voice verdict); ¶4: 'the stock's sky-high pre-leak valuation' (loaded wording in the outlet's own voice); calls the results 'positive' but never gives the trial's finding, the 42% lower risk of recurrence or death that CNN and Just the News report
Splits: Market story: Moderna down about 26% by 2 p.m. after Phase 3 data surfaced early on Oncology Central, Citi's valuation downgrade, billionaire shareholders' losses
- Broken. Rule: own-voice claim/analysis (¶6: 'Moderna has been on a remarkable—and likely unsustainable—trajectory' (own-voice verdict))
- Broken. Rule: loaded wording (¶4: 'the stock's sky-high pre-leak valuation' (loaded wording in the outlet's own voice))
- Broken. Rule: omission (calls the results 'positive' but never gives the trial's finding, the 42% lower risk of recurrence or death that CNN and Just the News report)
Same story: CNN, Just the News